eFFECTOR Therapeutics, Inc. (EFTR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
eFFECTOR Therapeutics, Inc. (EFTR) trades at $0.00 with AI Score 36/100 (Grade D). eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing selective translation regulator inhibitors for cancer treatment. Market cap: $2,823, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for EFTR: EFTR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EFTR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EFTR: 1/1 perspectives are bearish.
How is this calculated? →eFFECTOR Therapeutics, Inc. (EFTR) Healthcare & Pipeline Overview
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in selective translation regulator inhibitors for cancer. Its lead product candidate, Tomivosertib, targets metastatic non-small cell lung cancer, while Zotatifin addresses solid tumors. The company operates in the competitive biotechnology sector, seeking to advance novel cancer therapies.
What Is the Investment Thesis for EFTR?
eFFECTOR Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biopharmaceutical companies. The company's value hinges on the successful clinical development and potential regulatory approval of its lead product candidates, Tomivosertib and Zotatifin. Positive Phase 2b trial results for Tomivosertib in metastatic NSCLC could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisition offers. Similarly, advancement of Zotatifin through Phase 2 trials for solid tumors would bolster the company's pipeline and valuation. However, the company's reliance on a limited number of drug candidates and the inherent uncertainties of clinical trials pose substantial risks. As of 2026, the company's market capitalization is $0.00B, reflecting the speculative nature of its valuation.
Based on FMP financials and quantitative analysis
EFTR Key Highlights
- Lead product candidate Tomivosertib is in Phase 2b clinical trial for metastatic non-small cell lung cancer.
- Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), is in Phase 2 clinical trial to treat patients with solid tumors.
- Collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E.
- The company was founded in 2012, indicating a relatively young company in the biotech space.
- The company has 14 employees, reflecting its status as a small, clinical-stage biopharmaceutical company.
Who Are EFTR's Competitors?
EFTR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EFTR's Key Strengths?
- Novel approach to cancer treatment through selective translation regulation.
- Two drug candidates in Phase 2 clinical trials.
- Collaboration with Pfizer Inc.
- Experienced management team with expertise in drug development.
What Are EFTR's Weaknesses?
- Limited financial resources as a small, clinical-stage company.
- Reliance on a small number of drug candidates.
- High risk of clinical trial failure.
- OTC market listing may limit access to capital.
What Could Drive EFTR Stock Higher?
- Phase 2b clinical trial results for Tomivosertib in metastatic NSCLC.
- Phase 2 clinical trial results for Zotatifin in solid tumors.
- Potential for new strategic partnerships or collaborations.
- Advancements in the understanding of translation regulation in cancer.
What Are the Key Risks for EFTR?
- Financial-distress signal — its Altman Z-Score of -13.56 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Tomivosertib or Zotatifin.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- OTC market listing and associated risks.
What Are the Growth Opportunities for EFTR?
- Advancement of Tomivosertib in NSCLC: The successful completion of the Phase 2b clinical trial for Tomivosertib in metastatic NSCLC represents a significant growth opportunity. Positive trial results could lead to accelerated regulatory pathways, potential partnerships with larger pharmaceutical companies, and ultimately, commercialization of the drug. The NSCLC market is substantial, with a global market size projected to reach billions of dollars, offering a significant revenue opportunity for eFFECTOR Therapeutics.
- Expansion of Zotatifin into Additional Solid Tumors: The ongoing Phase 2 clinical trial of Zotatifin in solid tumors provides an opportunity to expand its application to other cancer types. Positive results in the current trial could pave the way for additional clinical trials targeting different solid tumor indications, broadening the potential market for Zotatifin and increasing its commercial value. This expansion could significantly enhance the company's growth prospects.
- Strategic Partnerships and Collaborations: eFFECTOR Therapeutics' existing collaboration with Pfizer Inc. demonstrates the potential for strategic partnerships to drive growth. Securing additional collaborations with other pharmaceutical companies or research institutions could provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its drug candidates. These partnerships can be crucial for navigating the complex and capital-intensive biotechnology landscape.
- Exploration of New Translation Regulator Targets: eFFECTOR Therapeutics' expertise in selective translation regulation positions it to explore new drug targets within this pathway. Identifying and developing inhibitors for other key regulators of mRNA translation could lead to the discovery of novel cancer therapies and expand the company's pipeline beyond Tomivosertib and Zotatifin. This diversification strategy could mitigate the risk associated with relying on a limited number of drug candidates.
- Out-licensing or Acquisition Opportunities: Positive clinical trial data and promising preclinical results could make eFFECTOR Therapeutics an attractive acquisition target for larger pharmaceutical companies seeking to expand their oncology portfolios. Alternatively, the company could out-license its drug candidates to other companies for further development and commercialization, generating revenue and reducing its financial burden. These exit strategies represent potential growth opportunities for eFFECTOR Therapeutics and its investors.
What Opportunities Does EFTR Have?
- Positive clinical trial results could lead to partnerships or acquisition.
- Expansion of drug candidates into additional cancer indications.
- Securing additional funding through grants or venture capital.
- Advancements in understanding of translation regulation in cancer.
What Threats Does EFTR Face?
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and potential delays in drug approval.
- Unfavorable clinical trial results.
- Changes in the regulatory landscape for cancer therapeutics.
What Are EFTR's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in selective translation regulation.
- Clinical trial data demonstrating efficacy and safety.
- Strategic collaborations with established pharmaceutical companies.
- First-mover advantage in targeting specific translation regulators.
What Does EFTR Do?
eFFECTOR Therapeutics, Inc., founded in 2012 and headquartered in Solana Beach, California, is a clinical-stage biopharmaceutical company dedicated to developing selective translation regulator inhibitors for cancer treatment. The company's primary focus is on modulating key pathways involved in cancer cell growth and survival through targeted therapies. Their lead product candidate, Tomivosertib, is an oral small-molecule inhibitor of MNK (MAPK-integrating kinase) currently in a Phase 2b clinical trial for patients with metastatic non-small cell lung cancer (NSCLC). Tomivosertib aims to disrupt cancer cell proliferation by targeting MNK, a key regulator of mRNA translation. In addition to Tomivosertib, eFFECTOR Therapeutics is developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4A), a crucial protein involved in the initiation of protein synthesis. Zotatifin is currently in a Phase 2 clinical trial for the treatment of patients with solid tumors. By inhibiting eIF4A, Zotatifin aims to selectively block the translation of oncogenic mRNAs, thereby suppressing tumor growth. eFFECTOR Therapeutics also has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E, further expanding its portfolio of translation regulator inhibitors. The company's strategic focus on selective translation regulation positions it within the innovative edge of cancer therapeutics, aiming to provide novel treatment options for patients with significant unmet medical needs.
What Products and Services Does EFTR Offer?
- Develop selective translation regulator inhibitors for cancer treatment.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Focus on modulating key pathways involved in cancer cell growth and survival.
- Target metastatic non-small cell lung cancer with Tomivosertib.
- Develop Zotatifin for the treatment of patients with solid tumors.
- Collaborate with Pfizer Inc. to develop inhibitors of eIF4E.
How Does EFTR Make Money?
- Develop and patent novel therapeutic candidates.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Potentially commercialize drugs directly or through partnerships.
- Generate revenue through drug sales, licensing agreements, or collaborations.
What Industry Does EFTR Operate In?
eFFECTOR Therapeutics operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and substantial financial investments. The oncology therapeutics market is a significant segment within the biotechnology industry, driven by the increasing prevalence of cancer and the demand for more effective and targeted treatments. eFFECTOR's focus on selective translation regulator inhibitors aligns with the industry trend toward precision medicine and personalized cancer therapies. Competitors include companies developing similar targeted therapies, as well as established pharmaceutical giants with extensive oncology portfolios. The success of eFFECTOR Therapeutics depends on its ability to differentiate its products, navigate the complex regulatory landscape, and secure strategic partnerships.
Who Are EFTR's Key Customers?
- Patients with cancer, specifically non-small cell lung cancer and solid tumors.
- Healthcare providers who prescribe and administer cancer treatments.
- Pharmaceutical companies seeking to acquire or license novel cancer therapies.
- Research institutions and collaborators involved in drug development.
FY2026 estForward Outlook
Wall Street analysts project eFFECTOR Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-21.00.
EFTR Valuation & Market Position
With a 3K market cap, eFFECTOR Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, EFTR's quantitative score of 36/100 is below the peer average of 76/100.
F-Score 2/9Financial Health
eFFECTOR Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.56 places it in the distress zone, a signal of elevated financial risk.
Company Profile
eFFECTOR Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Solana Beach, US. The company is led by CEO Davide Ruggero. EFTR has traded publicly since 2021.
EFTR Financials
Bull Case vs Bear Case
Bull Case
- eFFECTOR's recent insider buying suggests those in the know see long-term value, a potential confidence booster for other investors.
- The community's generally optimistic outlook on eFFECTOR's potential drug advancements is creating positive buzz.
- Market perception seems to be shifting towards recognizing the unmet needs in eFFECTOR's therapeutic areas, potentially driving future interest.
- Recent developments in similar biotech companies have created a halo effect, improving sentiment around eFFECTOR's prospects.
Bear Case
- Despite positive community sentiment, some investors are wary of the high-risk nature of early-stage biotech companies like eFFECTOR.
- Recent market volatility has increased risk aversion, making investors less willing to invest in speculative biotech stocks.
- Some community members express concerns about eFFECTOR's ability to secure future funding, potentially hindering their development pipeline.
- While there's optimism, the success of eFFECTOR's therapies is still unproven, leading to skepticism among seasoned biotech investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
EFTR Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 13, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Apr 27, 2022
EFTR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EFTR.
Price Targets
Wall Street price target analysis for EFTR.
EFTR MoonshotScore
What does this score mean?
The MoonshotScore rates EFTR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Davide Ruggero
CEO
Davide Ruggero is the CEO of eFFECTOR Therapeutics, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has a proven track record in leading and managing research and development programs, as well as driving strategic initiatives. Ruggero's expertise spans various aspects of drug discovery, clinical development, and commercialization. He is responsible for overseeing the overall direction and operations of eFFECTOR Therapeutics.
Track Record: Under Davide Ruggero's leadership, eFFECTOR Therapeutics has advanced its lead product candidates, Tomivosertib and Zotatifin, into Phase 2 clinical trials. He has also secured a collaboration agreement with Pfizer Inc., demonstrating his ability to forge strategic partnerships. Ruggero has focused on building a strong team and fostering a culture of innovation within the company.
EFTR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that eFFECTOR Therapeutics may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume leads to higher price volatility.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's capitalization structure and ownership.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Existence of a collaboration agreement with Pfizer Inc.
- Advancement of drug candidates into Phase 2 clinical trials.
- Experienced management team with expertise in drug development.
- Focus on a specific therapeutic area (cancer).
- Company was founded in 2012, indicating several years of operation.
eFFECTOR Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does eFFECTOR Therapeutics, Inc. do?
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate, Tomivosertib, is in Phase 2b clinical trial for metastatic non-small cell lung cancer. They are also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 2 clinical trial to treat patients with solid tumors. The company aims to provide novel treatment options for patients with significant unmet medical needs.
What are the main risks for EFTR?
The main risks for eFFECTOR Therapeutics include the inherent uncertainties of clinical trials, the potential for regulatory setbacks, and the intense competition within the biotechnology industry. Specifically, failure to achieve positive results in the Phase 2b trial for Tomivosertib or the Phase 2 trial for Zotatifin could significantly impact the company's value. Additionally, the company's limited financial resources and reliance on external funding make it vulnerable to market fluctuations and funding constraints. The OTC market listing also presents unique risks related to liquidity and regulatory oversight.
What are the key factors to evaluate for EFTR?
eFFECTOR Therapeutics, Inc. (EFTR) holds an AI score of 36/100 (low). Not financial advice.
How frequently does EFTR data refresh on this page?
EFTR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EFTR's recent stock price performance?
eFFECTOR Therapeutics, Inc. (EFTR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach to cancer treatment through selective translation regulation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EFTR overvalued or undervalued right now?
Valuing eFFECTOR Therapeutics, Inc. (EFTR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EFTR?
Before investing in eFFECTOR Therapeutics, Inc. (EFTR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EFTR to a portfolio?
Key strength of eFFECTOR Therapeutics, Inc. (EFTR): Novel approach to cancer treatment through selective translation regulation. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending and may provide additional insights.
- OTC market data may be limited or unreliable.